crisaborole

Modality

small molecule

Mechanism

12.1 Mechanism of Action Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined.

Targets

PDE4

Storage

—

Approved

atopic dermatitis — FDA

In trial

seborrheic dermatitis, atopic dermatitis, alopecia areata, vitiligo

Sources

DailyMed (FDA label)DrugBank ClinicalTrials.gov

Last verified

2026-04-23

No curated MOA diagram yet. See lib/moa-data.ts for the shape; add an entry keyed by crisaborole.

Formulations

2% ointment